Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Company should release a PR or letter to shareholders updating on current events & future plans.
$NSPX
Financials only matter to become Current. It is the future financials that will be important with the company's new business model in the Cannabis sector. Would like to see the Name & Symbol change get done quickly to reflect Acqua Cannabis (AQCB or AQCA).
$RMRK
Excellent post!!! Crazy undervalued here. I'm expecting a major correction in Market Cap soon.
$NSPX
I added 500K shares today at .003. Holding 2M shares for the run into multi-pennies. Someone is holding this down. Possibly, last of the conversion shares & a few retail flippers. Bring the news to leave them chasing much higher!!!
$NSPX
I will add another 200K again in a minute.
$NSPX
Im going to add another 200K shares now at .003. It is time to start slapping the ask.
$NSPX
He is definitely still the CEO according to the last SEC filing this month.
By Order of the Board of Directors
Of Inspyr Therapeutics, Inc.
/s/ Christopher Lowe
Christopher Lowe
Chief Executive Officer
January
The R/S announcement definitely shook out a lot of traders. Usually, I would have bailed as well but that is with most other stinky pinkies that have bloated O/S & A/S in the billions with no proven products. This company only has 150M A/S & they aren't raising it. My average was in the high .005s before the announcement but I've been averaging down at these levels to get my DCA in the low .004s. Also, this company is on the brink of having a cancer drug if they can get the financial backing which I believe is in motion with our CEO via partnership or merger. Plus, lets not forget its deal with Ridgeway to license its oncology related compounds which could lead to $12M in milestone payments & receive royalties thereafter when commercialized. Potential is massive here!!! It only takes one decent size trading group to run this tiny float to pennies even without any news being released.
$NSPX
O/S = 122.3M from last filing with A/S = 150M. Float is close to being locked up. Once, news is released this will move north quickly. R/S cannot happen until company becomes current & then has to file a Definitive 14C with the SEC thereafter. Also, the split determined by the BOD could be as little as 2 to 1. I believe the split will be authorized only for uplisting to a higher exchange if needed if the PPS doesn't reach the requirement organically. This all depends on partnership or reverse merger. This has the potential with this share structure to have an OW*P move. Definitely worth the risk at these levels. GLTU
FINRA Operations Determination
Once an issuer or its duly authorized representative submits a Company-Related Action Notification Form, FINRA Operations will review the submission and may request additional information or documentation as may be necessary to verify the accuracy of the information. If the party that submits the form does not sufficiently respond within 90 calendar days of the date FINRA Operations requests additional information or documentation, the request will be deemed "lapsed" and will be closed.
During the course of the review, if FINRA Operations believes that one of five explicitly enumerated factors outlined in Rule 6490 may be triggered, it generally will conduct an in-depth review of the Company-Related Action and may seek additional information or documentation from the issuer or duly authorized representative as outlined above. Where a Company-Related Action is deemed deficient, FINRA Operations may determine that it is necessary for the protection of investors, the public interest and to maintain fair and orderly markets, that documentation related to a Company-Related Action will not be processed. Factors that may be considered by the FINRA Operations in finding a request to process documentation related to a Company-Related Action deficient are explicitly limited to the following:
1. FINRA staff reasonably believes the forms and all supporting documentation, in whole or in part, may not be complete, accurate or with proper authority;
2. the issuer is not current in its reporting obligations, if applicable, to the SEC or other regulatory authority;
3. FINRA has actual knowledge that parties related to the Company-Related Action are the subject of pending, adjudicated or settled regulatory action or investigation by a regulatory body, or civil or criminal action related to fraud or securities laws violations4;
4. a government authority or regulator has provided information to FINRA, or FINRA has actual knowledge, indicating that persons related to the Company-Related Action may be potentially involved in fraudulent activities related to the securities market and/or pose a threat to public investors; and/or
5. there is significant uncertainty in the settlement and clearance process for the security.
Notice Chris is on the BOD for the companies below. I believe a partnership with Hansen Medical or R/M with Pacific Pharmaceuticals could be on the table to initiate Phase III trials of its cancer drug Mipsagargin. Time will tell.
Chris currently sits on the Board of Directors of the following public and private companies: Hansen Medical (NASDAQ: HNSN; 2006-present); Pacific Pharmaceuticals (private; 2010-present); and Career Closet (Non Profit; 2009-present).
$NSPX
Wow!!! Very impressive credentials!!! Big things about to be revealed here soon.
$NSPX
Chris Lowe
Chris Lowe joined FLG in 2014, serves on the Firm’s Management Committee and was elected Co-Managing Partner in 2018. Chris has over 15 years of senior management experience as President, CBO and CFO of various private and public life sciences, medical technology, and technology companies. Additionally, he has served as a member of the Board of Directors of both public and private companies, and has chaired their respective Audit Committees and Compensation Committees. Chris helps companies succeed by assisting them with corporate and financial strategy, including early stage financing, successive fundraising and IPOs, public company advising and Wall Street communications, licensing transactions, M&A, restructurings and coaching at every level of the C-Suite. In particular, he excels at helping companies navigate the challenges of accessing capital, M&A, licensing, restructurings and exits. During his career as a C-level executive, Chris has successfully raised over $500M in private and public financings, completed over $1.0B in M&A transactions, negotiated over $300M in debt instruments for companies, and has overseen three SOX-404 implementations. As VP and CAO, he drove a parallel M&A and IPO path resulting in the sale of Peninsula Pharmaceuticals to Johnson & Johnson for over $300M in 2005, including the design of a tax efficient spinout for assets which were undervalued by Johnson & Johnson. As CFO of Asthmatx, a medical technology company, he actively drove strategic supply negotiations and led the parallel M&A and IPO process resulting in a $50M strategic investment from Olympus Medical and ultimately the sale of the company to Boston Scientific in a deal valued at approximately $400M. As its Chief Financial Officer, he also took Anthera Pharmaceuticals, a pharmaceutical development company, public in 2010 during the height of the financial crisis, raising over $300M in both the private and public markets during his tenure. Prior to joining FLG, Chris recently served as a strategy, financial and management consultant to several public and private companies, assisting them with financings, market due diligence, Wall Street communications, and exits. Chris earned his B.S. from California Polytechnic State University – San Luis Obispo, and a MBA from St Mary’s University. Chris currently sits on the Board of Directors of the following public and private companies: Hansen Medical (NASDAQ: HNSN; 2006-present); Pacific Pharmaceuticals (private; 2010-present); and Career Closet (Non Profit; 2009-present).
Product Development of Adenosine Receptor Modulators
https://www.sec.gov/Archives/edgar/data/1421204/000161577417006918/s108227_10q.htm
Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation. High levels of adenosine in the tumor microenvironment inhibits immune response mediated through the A2A and A2B receptors. Adenosine also plays a role in non-malignant conditions where it is rapidly increased in response to inflammation, hypoxia, ischemia, or trauma. Adenosine released in this setting has been shown to have a protective effect and limits excessive inflammatory damage to tissues.
The adenosine receptor antagonists have broad applicability as a potential immuno-oncology (IO) therapeutic agent in multiple tumor types both as a single agent and in combination with other IO agents, in addition to traditional cytotoxic chemotherapy. We are actively seeking licensing opportunities and/or partners to further development our A2A, A2B and dual A2A/A2B receptor antagonists. Our current product development plan for adenosine receptor antagonists contemplates the following major initiatives:
License and/or partner to companies intending to further the develop the A2A, A2B and/or dual A2A/A2B receptor antagonists.
Further characterization of existing agents, specifically the A2B and dual A2A/A2B receptor antagonists, toward IND enabling studies and support ongoing licensing/partnership activities.
Conduct IND enabling studies.
Conduct clinical studies with one or more of the adenosine receptor antagonists.
Continue generating additional adenosine receptor antagonists to expand our portfolio.
The adenosine receptor agonists have applicability in a broad range of non-oncology conditions including inflammatory and autoimmune diseases and conditions. We are actively seeking licensing opportunities and/or partners to further development our A2A receptor agonists. Our current product development plan for adenosine receptor agonists contemplates the following major initiatives:
License and/or partner to companies with development expertise in the intended indication.
Further characterize existing agents to support licensing/partnership activities.
Continue generating additional adenosine receptor agonists to expand our portfolio.
$NSPX
Inspyr to License Oncology Related Compounds to Ridgeway Therapeutics Inc.
https://markets.businessinsider.com/news/stocks/inspyr-to-license-oncology-related-compounds-to-ridgeway-therapeutics-inc-1027539438
WESTLAKE VILLAGE, Calif., Sept. 17, 2018 Inspyr Therapeutics announced today that it has entered into an agreement with Ridgeway Therapeutics Inc. in which Ridgeway will license and assume control of certain assets relating to Inspyr's oncology development programs, including intellectual property rights relating to adenosine antagonists owned by Inspyr.
Adenosine receptors have a variety of functions in the body that are expressed through four subtypes (A1, A2A, A2B, and A3). The adenosine A2 receptor subtypes (A2R) are of particular interest as potential targets for the treatment of cancer. Extremely high levels of adenosine are found locally in the tumor microenvironment. These have a direct immunosuppressive effect on T-cells and other cell types that would otherwise attack and kill cancer cells. Inhibition of the A2R has the potential to reverse these immunosuppressive effects.
Inspyr and Ridgeway will collaborate on certain aspects of development which will include a minimum level of purchased services by Ridgeway within 18 months of this transaction. In addition, Inspyr is eligible for approximately $12 million in success-based milestones from the Transaction. Inspyr is also entitled to receive royalties on all commercial sales. In the event Ridgeway sub-licenses these assets, Inspyr is entitled to share in the proceeds of any future transaction.
$NSPX
Product Development of Mipsagargin
https://www.sec.gov/Archives/edgar/data/1421204/000161577417006918/s108227_10q.htm
Mipsagargin is a prodrug targeting the tumor vasculature that has therapeutic potential in a wide range of malignancies. However, hepatocellular carcinoma, with promising Phase II study results, is our most advanced indication and our initial continued clinical focus. We are actively seeking a potential development and commercialization partner at both multi-national and regional levels to assist with the development of mipsagargin through clinical trials in liver cancer. Our current product development plan of mipsagargin contemplates the following major initiatives:
?
Initiation of our next clinical trial in patients with advanced HCC which includes clinical dose optimization.
?
Continuation of ongoing business development discussions with potential development partners.
?
Continued evaluation of single agent mipsagargin and mipsagargin combinations in nonclinical studies of other PSMA expressing tumors through collaboration with leading researchers in oncology.
$NSPX
Good article about Mipsagargin.
https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2017/NSPXD-Update-on-Development-of-Mipsagargin-article/default.aspx
$NSPX
Name & ticker symbol change will be huge to reflect the company's new direction & business model.
Acqua Cannabis - AQCB
$RMRK
Correct. It hasn't traded on any Canadian exchange since 2009.
I think it does not trade in Canada. Maybe part of the deception.
Incorrect. The split occurred on 21 December with the brokerage firms. The PPS was .009 the day before. The PPS should have been adjusted to $4.98 but it wasn't. Stating & filing that a consolidation is complete doesn't make it complete until the shares are actually reduced from shareholders brokerage accounts. If the consolidation actually took place in June then those shares purchased after would be post-split shares but the split never officially occurred. I owned 200K shares on 20 December & on the 21st it was changed to 361. That is a 553-1 R/S that supposedly occurred in June but never did. We all thought we were buying post-split shares since OTC Markets & the Company's Transfer Agent stated the O/S was 1.67M. Dina brought it to our attention that the split never actually occurred according to FINRA back in June or July. Also, GG contacted the CEO Carmelo who stated the split hasn't occurred in the U.S. yet but has taken place in Canada which is pure BS since this ticker only trades in the US on the OTC market.
The pre-split price was .0005
OTC Markets isn't showing RYSMF completed a R/S. The link below provides all the most recent R/S of OTC companies. Yet, my account shows otherwise. FINRA stated CUSIP change only. So, the company needs to return our shares or complete the R/S. 553 to 1 R/S from closing price of Friday would put the PPS at $1,493. This stock has a very good chance of being suspended on what has transpired & both FINRA & SEC is investigating the current situation. This could turn into a very profitable situation for both pre-spit/post-split owners or a complete total loss. Time will tell once the regulators sort it all out. GLTA
https://www.otcmarkets.com/market-activity/compliance-statistics
$RYSMF
Shouldn't take long if proper paperwork is filed correctly. Just have to submit paperwork with State of Incorporation & FINRA. Could be completed in January easily if Company gets the ball rolling now.
$RMRK - $AQCB (Acqua Cannabis)
Great!!! Looks you or someone on this board got the answer from the tweet.
$RMRK
Company needs to submit with FINRA for a Name & Symbol Change to Acqua Cannabis Corp. to relate to its new business model. AQCB is available for new ticker. This will help bring in new investors. Most traders/investors think this is a mining company when they see the name & ticker symbol.
$RMRK
Agree 100%. Notice this new character who comes on here & claims he worked for FINRA in the past. Someone getting nervous of this illegal sh*t going down here. No adjustment come Monday I'll let the SEC decide.
There was never adjusted end of story
Exactly!!! If the PPS adjusted to $4.98 do you really think someone would sell shares at .01. LMFAO
True, but it never adjusted. It still has to adjust before someone sells below post adjusted PPS.
We understand a CUSIP change has to be done with splits due to new share certificates have to be issued. The problem is this traded on Friday without the adjusted PPS of the split & some brokers allowed trading of their pre-split shares which has now caused an unfortunate short position for some who sold their pre-split shares. My broker (TDA) had our shares locked from trading but I believe E-Trade didn't lock down the pre-split shares. If the PPS doesn't adjust by Monday then their is definitely some illegal action going on here & I'll be contacting the SEC. Also, the Transfer agent was releasing info before the split that the O/S was 1.67M which clearly wasn't the case.
RYSMF doesn't trade on a Foreign Market. They are a foreign company that trades on the US market. Also, it wasn't just a CUSIP change. Everyone who owned shares in the U.S. at least had their shares split on Friday. The issue is the PPS didn't adjust to the split.
I USED TO WORK AT FINRA .RYSMF IS A FOREIGN STOCK SO WHEN FINRA SAID 1-553 REVERSE SPLIT EFFECTIVE ON 6/28/18 , THEY WERE WERE TALKING ABOUT FOREIGN MARKET NOT US MARKET .FINRA DID CUSIP CHANGE ON 12/21/18 TO EFFECT R/S ON US MARKET . LOOK UP DEFINITION OF CUSIP CHANGE .
I agree with you on the Canadians shares being adjusted & the reason the PPS went up on trading but the adjustment value for the split hasn't transpired since it trades on the US Market. The Canadian shareholders value of their consolidated shares will now transpire in value. It actually benefited the Canadian shareholders because the PPS was lower back then & their consolidated shares have been restricted from trading & the PPS is higher when the split occurred.
Good morning Dina, the PPS hasn't been adjusted for the R/S. If the PPS was .002 a 553 to 1 R/S would make the PPS $1.11. The 52-week high of this stock came on Friday at .126 & closed at .125. If the Canadian brokers consolidated their shares back in June or July (Conflicting what their PR states & FINRA) it didn't effect the PPS since this trades only on OTC Markets which is U.S.. This should open at $4.98 on Monday for the PPS adjustment from .009 which was the closing on Thursday. 553 x .009 = $4.98. The value of my pre-split shares should equal the value of my post-split shares until it trades again. I talked to my broker & he was confused why the PPS didn't get adjusted & stated sometimes it takes longer to adjust & should be by Monday. I've never seen it take longer to adjust. Usually, every broker locks the pre-split shares & the ticker trades with a letter D at the end of the symbol until all the new share certificates are distributed to all the brokers from the company's transfer agent. It can take up to a few weeks before all the brokers receive all the new certs. You can buy & sell the new shares on the open market with the new symbol & PPS adjustment. Most of the larger brokers will receive the new shares between 1 to 3 days.
BTW - You were spot on about the R/S.
https://finance.yahoo.com/quote/RYSMF?p=RYSMF&.tsrc=fin-srch
So i think it´s already adjusted because many could not sell and this was the reason it could go up from .002 to $.10.
If it was just a CUSIP change our shares wouldn't have been split.
No, he didn't know why it didn't adjust either. He stated it should adjust by Monday.
Yeah, I'm sure they charged me the fee too. I was livid when I was talking to the TDA rep on why the PPS didn't get adjusted but my shares did.
Yeah, I wish I grabbed some now. I was tempted in the morning but thought it was just a CUSIP change & not a split too. You're going to make some serious money when the PPS adjusts. Congrats!!
I didn't sell any of my pre-split shares. TDA had them locked under a numbers symbol & my shares adjusted post-split around 3:00.
Well, if they don't fix this cluster f*ck come Monday I might file a complaint with the SEC. The PPS better be adjusted to $4.98.
Good for him but not for the others who were allowed to sell their pre-split shares who now will be short due to the incompetence of their brokerage firms & FINRA. The PPS should have adjusted & nobody should have been able to buy or sell their pre-split shares.
That is another problem all in itself. The PPS never adjusted post-split so you bought shares at a 553 per share discount. All sorts of legality issues on this cluster fuck of a ticker.
Did the shares you bought yesterday split as well?
$RYSMF
The PPS should be $4.98 before open on Monday & the symbol should be RYSMFD. The letter D is always added at the end of the ticker after a split. Also, you still might not be able to trade your shares come Monday until your brokerage firm receives the new shares from the transfer agent.
$RYSMF
This was the reply I got from the TA on 12 December.
From: +TMXE Investor Services <tmxeinvestorservices@tmx.com>
Date: 12/12/18 11:30 AM (GMT-05:00)
To: XXX@yahoo.com
Subject: Re: [EXTERNAL] Transfer Agent Services
Hello Jeremy,
1,665,119 outstanding shares for Royal Standard Inc.
Regards,
Investor Services
TSX TRUST COMPANY
E tmxeinvestorservices@tmx.com < Caution-mailto:tmxeinvestorservices@tmx.com >
TOLL-FREE 1 866 600-5869
T + 416 342-1091
F + 416 361-0470
M 301 – 100 Adelaide Street West, Toronto, ON M5H 4H1
For more information, visit the Investor Centre Frequently Asked Questions (FAQ) page:
Caution-www.tsxtrust.com/resources/investor-centre/faq < Caution-http://www.tsxtrust.com/resources/investor-centre/faq >
TMX | Caution-www.tmx.com < Caution-http://tmx.com/ >